HealthEquity (NASDAQ:HQY) Stock Rating Lowered by Wall Street Zen

HealthEquity (NASDAQ:HQY) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Sunday.

Other equities analysts have also recently issued research reports about the stock. Citizens Jmp increased their price target on shares of HealthEquity from $117.00 to $122.00 and gave the stock a “market outperform” rating in a research report on Thursday, December 4th. Barclays began coverage on HealthEquity in a report on Monday, December 8th. They set an “overweight” rating and a $118.00 target price on the stock. BTIG Research reissued a “buy” rating and set a $130.00 price target on shares of HealthEquity in a research report on Thursday, December 4th. Citigroup restated an “outperform” rating on shares of HealthEquity in a research note on Thursday, December 4th. Finally, The Goldman Sachs Group downgraded shares of HealthEquity from a “neutral” rating to a “sell” rating and set a $89.00 price objective for the company. in a report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $119.60.

HealthEquity Stock Performance

Shares of HQY opened at $84.56 on Friday. The business’s 50 day moving average is $96.84 and its two-hundred day moving average is $94.99. HealthEquity has a 52-week low of $74.07 and a 52-week high of $116.65. The firm has a market cap of $7.22 billion, a price-to-earnings ratio of 38.79, a PEG ratio of 1.36 and a beta of 0.20. The company has a quick ratio of 4.13, a current ratio of 4.13 and a debt-to-equity ratio of 0.46.

HealthEquity (NASDAQ:HQY) last issued its quarterly earnings results on Wednesday, December 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. HealthEquity had a net margin of 14.86% and a return on equity of 12.94%. The business had revenue of $322.16 million during the quarter, compared to analyst estimates of $320.92 million. During the same quarter in the previous year, the firm earned $0.78 earnings per share. The business’s revenue was up 7.2% compared to the same quarter last year. HealthEquity has set its FY 2026 guidance at 3.870-3.950 EPS. Analysts forecast that HealthEquity will post 2.32 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Elimelech Rosner sold 10,959 shares of the business’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $95.45, for a total transaction of $1,046,036.55. Following the completion of the transaction, the executive vice president owned 45,742 shares of the company’s stock, valued at approximately $4,366,073.90. The trade was a 19.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Delano Ladd sold 1,500 shares of the company’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $94.72, for a total transaction of $142,080.00. Following the transaction, the executive vice president owned 73,979 shares of the company’s stock, valued at $7,007,290.88. This represents a 1.99% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 15,459 shares of company stock worth $1,483,062 over the last quarter. 1.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On HealthEquity

Several hedge funds and other institutional investors have recently made changes to their positions in HQY. Xponance Inc. increased its position in HealthEquity by 0.8% in the 3rd quarter. Xponance Inc. now owns 12,265 shares of the company’s stock valued at $1,162,000 after acquiring an additional 102 shares during the period. Nisa Investment Advisors LLC grew its stake in shares of HealthEquity by 2.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,787 shares of the company’s stock worth $397,000 after purchasing an additional 108 shares in the last quarter. Advisors Asset Management Inc. grew its stake in shares of HealthEquity by 4.7% in the second quarter. Advisors Asset Management Inc. now owns 2,437 shares of the company’s stock worth $255,000 after purchasing an additional 110 shares in the last quarter. Fiduciary Trust Co increased its holdings in shares of HealthEquity by 3.4% during the third quarter. Fiduciary Trust Co now owns 3,669 shares of the company’s stock valued at $348,000 after purchasing an additional 120 shares during the period. Finally, Larson Financial Group LLC raised its stake in shares of HealthEquity by 24.4% during the third quarter. Larson Financial Group LLC now owns 628 shares of the company’s stock valued at $60,000 after purchasing an additional 123 shares in the last quarter. 99.55% of the stock is currently owned by institutional investors and hedge funds.

About HealthEquity

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.